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COOPERATIVE GROUPS: SPT
† In memory of Prof. Gérard Siest (April 9th, 2016)
and his contribution to the creation of the SPT
With the development of modern drugs, it quickly be-
came apparent that not all individuals respond equally to 
drug therapy. Outcomes can be multiple, ranging from 
a good response to non-efficacy, adverse drug reactions, 
or toxicity. Differences in response are attributed in part 
to environmental factors and to the individual’s genetic 
predispositions [1]. The progress of molecular sciences en-
abled the understanding of drug mechanism, inevitably, 
exposing the underlying molecular differences between 
individuals and diseases that influence pharmacokinetics 
and pharmacodynamics of the drugs. This, in turn, gives 
the opportunity to identify individuals and diseases that 
will react differently to the given drug based on their 
genetic composition. The study of how individuals re-
spond to drugs because of their genetic background has 
been termed pharmacogenetics or pharmacogenomics [1]. 
Pharmacogenomics is thus a multidisciplinary science 
with the great potential to translate findings to benefit 
the patients by individualizing therapy and provide new 
targets for drug development [1]. Combining such a di-
verse array of approaches stipulates a need for a platform 
broad enough to be able to address the most challenging 
problems of individualized medicine. For this reason The 
European Society of Pharmacogenomics and Personalized 
Therapy (ESPT) was established to offer the opportunity 
to exchange information, share ideas over a broad spec-
trum of scientific disciplines [2].
On the 3rd of February 2016 a constitutive assembly of 
the Swiss Group of Pharmacogenomics and Personalized 
Therapy (SPT) was held in Bern. The SPT was created as 
a section within the Swiss Society of Pharmacology and 
Toxicology Clinics (SSCPT, President: Dr. Hugo Kupfer-
schmidt) by researchers active in the field of pharmacoge-
nomics and will serve as a Swiss national point for the 
ESPT (Chairman: prof. Gerard Siest†, Nancy). The SPT 
group aims to build and promote the goals of the ESPT, 
which are «leadership and innovation in science and educa-
tion to enhance the scientific basis and quality of diagnosis 
and therapy for patients throughout the world.» For this 
reason both societies combine and welcome experts from 
various fields of basic molecular and biochemical sciences, 
to clinically oriented sciences and practitioners such as 
hospital clinicians, pharmacologists and pharmacists. The 
ESPT specifically offers opportunities for easy and flexible 
creation of subgroups and committees within the society 
such as scientific and clinical implementation committees 
for: Drug Transporters, Endobiotic and Drug interaction, 
Transcription factors and Pediatric individualized treatment 
in oncology and hematology committees. These commit-
tees aim to promote cooperation between individuals and 
institutions and to facilitate transfer and harmonization of 
pharmacogenetic testing, to bring together basic and trans-
lational research, to educate health professionals throughout 
Europe and to become a partner for industry and regulatory 
bodies [2]. Along with scientific work, the ESPT strongly 
emphasizes education by implementing an annual school of 
Pharmacogenomics, annual ESPT congress and publication 
of its official journal Drug metabolism and personalized 
therapy (www.esptnet.eu). The ESPT emphasizes informal 
structure that allows for a greater personal initiative. The 
society encourages dynamic national activity, which is why 
the creation of the SPT was warmly welcomed.
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